Artificial Intelligence

Sinusitis Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market – Optinose, GeneOne Life Science, Lyra, Sanofi, Regeneron, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer

Published

1 year ago

May 9, 2023

<!– Name:DistributionId Value:8831877 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:19cd81b4-73a6-41ad-b0c8-6e6bedb3ab35 –>

New York, USA, May 09, 2023 (GLOBE NEWSWIRE) — Sinusitis Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market – Optinose, GeneOne Life Science, Lyra, Sanofi, Regeneron, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer

The sinusitis market is anticipated to surge due to the factors such as the launch of novel drugs, increasing healthcare spending and improved diagnosis during the forecasted period (2023–2032) in the 7MM.

DelveInsight’s Sinusitis Market Insights report includes a comprehensive understanding of current treatment practices, sinusitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Sinusitis Market Report

As per DelveInsight analysis, the sinusitis market is expected to grow positively owing to several underline factors during the study period (2019–2032).
DelveInsight’s analysis shows that sinusitis cases show an increasing trend in the forecasted period in the United States.
Globally, leading sinusitis companies such as Optinose US Inc, GeneOne Life Science, Lyra Therapeutics, Sanofi, Regeneron Pharmaceuticals, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer, TRELLIS BIOSCIENCE, Sanotize Research and Development, OptiNose, Biohaven Pharmaceuticals, Keymed Biosciences Co.Ltd, Suzhou Connect Biopharmaceuticals, Ltd., BEAM Alliance, Insmed Incorporated, Lanier Biotherapeutics, GlycoMira, IVIEW Therapeutics Inc., Nota Laboratories LLC, Quorum Innovations, and others are developing novel sinusitis drugs that can be available in the sinusitis market in the coming years.
Some of the key therapies for sinusitis treatment include OPN-375, Quinine topical nasal spray, Mometasone eluting resorbable scaffold, Dupilumab, Omalizumab, Benralizumab, Telithromycin, Moxifloxacin, PF-06817024, and others.
Several sinusitis therapies are in various stages of development, and their anticipated launch will drive the sinusitis market forward.

Discover which therapies are expected to grab the major sinusitis market share @ Sinusitis Market Report

Sinusitis Overview

Sinusitis is one of the most common primary care diagnoses. It causes significant morbidity, often necessitating time away from work, and is one of the most common reasons why a general practitioner will prescribe antibiotics. Sinusitis is defined as inflammation of the mucosal lining of the paranasal sinuses. However, rhinosinusitis is a more correct word because sinusitis typically accompanies inflammation of the neighboring nasal mucosa. Rhinosinusitis is frequently categorized depending on the length of sinusitis symptoms and inflammation. Acute rhinosinusitis (ARS) is described as sinusitis symptoms lasting over 12 weeks. Chronic rhinosinusitis (CRS) is sinusitis symptoms lasting over 12 weeks. The majority of acute rhinosinusitis is viral in nature and improves on its own. It is critical to differentiate between viral and bacterial rhinosinusitis to avoid providing ineffective antibiotics against viral infections.

Sinusitis Epidemiology Segmentation

The sinusitis epidemiology section provides insights into the historical and current sinusitis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The sinusitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Sinusitis Prevalent Cases
Sinusitis Gender-specific Prevalent Cases
Sinusitis Type-specific Cases

Download the report to understand which factors are driving sinusitis epidemiology trends @ Sinusitis Epidemiological Insights

Sinusitis Treatment Market

Antibiotics, such as amoxicillin, have been suggested as first-line treatment for uncomplicated acute sinusitis for two weeks. The chosen antibiotic must be effective against S. pneumoniae, H. influenza, and M. catarrhalis. Because S. pneumoniae causes rare intracranial and ocular complications of acute bacterial sinusitis, comprehensive coverage for this pathogen is essential. Amoxicillin-clavulanate (Augmentin) is also an effective first-line treatment for acute sinusitis. The inclusion of clavulanate, a beta-lactamase inhibitor, improves H. influenzae and M. catarrhalis coverage. Because of S. pneumoniae resistance, greater amoxicillin dosages (90 mg/kg/day up to 2 g/day) should be investigated.

Cephalosporins such as cefpodoxime proxetil (Vantin) and cefuroxime (Ceftin) are further alternatives for sinusitis treatment. Trimethoprim-sulfamethoxazole (Bactrim), clarithromycin (Biaxin), and azithromycin (Zithromax) may be recommended in individuals allergic to beta-lactams, although they may not provide appropriate coverage for H. influenzae or resistant S. pneumoniae. Penicillin, erythromycin (Suprax), and first-generation cephalosporins such as cephalexin (Keflex, Keftab) are not advised for treating acute sinusitis due to poor antibiotic coverage of the main pathogens.

Mucolytic drugs (guaifenesin) can assist in reducing mucus viscosity for easier clearance and are frequently used in conjunction with decongestants. Some mucolytics are now available over the counter. Saline spray or irrigation can aid in the removal of secretions. Topical corticosteroids are not recommended for acute sinusitis but may benefit chronic sinusitis, nasal polyps, and allergic and nonallergic rhinitis. Antihistamines are not recommended for sinusitis but may be beneficial for underlying allergic rhinitis.

To know more about sinusitis treatment, visit @ Sinusitis Treatment Drugs

Key Sinusitis Therapies and Companies

OPN-375: Optinose US Inc
Quinine topical nasal spray: GeneOne Life Science
Mometasone eluting resorbable scaffold: Lyra Therapeutics
Dupilumab: Sanofi/Regeneron Pharmaceuticals
Omalizumab: Genentech
Benralizumab: AstraZeneca
Telithromycin: Sanofi
Moxifloxacin: Bayer
PF-06817024: Pfizer

Learn more about the FDA-approved drugs for sinusitis @ Drugs for Sinusitis Treatment

Sinusitis Market Dynamics

The sinusitis market is expected to change in the coming years. Sinusitis is a common cancer treatment modality. As a result, a large population suffers from sinusitis, creating a massive sinusitis market for any new entrant. Moreover, advancements in radiation delivery technology, such as intensity-modulated radiation treatment, can assist in reducing radiation-induced skin toxicity in specific tumour types, such as breast cancer, will also propel the sinusitis market growth. For those at increased risk of sinusitis, prophylactic administration of a topical steroid is preferred, and topical steroids are often used to treat acute instances. Furthermore, there is some interest in using topical antioxidants or oral enzymes to prevent sinusitis, but no apparent effect has been demonstrated yet.

Furthermore, there is a significant deal of interest in better understanding the processes of dermal injury to mitigate the dermatologic consequences of radiation therapy, but prospective data to guide management are currently scarce. Additionally, the sinusitis pipeline is highly robust; many possible therapies are being studied for sinusitis treatment, and it is safe to assume that the therapeutic space will substantially impact the sinusitis market throughout the forecast period.

However, certain factors may affect the growth of the sinusitis market. Despite developments in radiation delivery technology and rising attention to minimising skin responses, sinusitis management has no gold standard. There are few prospective randomised studies on the use of pharmacologic or supportive care treatments, both topical and non-topical, to prevent and cure sinusitis. Several off-label therapy options are now available on the sinusitis market, each with a sizable sinusitis market share and posing a significant challenge to any new entry in the sinusitis market.

Moreover, the sinusitis market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the sinusitis market growth. Furthermore, sinusitis treatment options in cancer have been steadily increasing. This increase in alternative medicines can potentially reduce sinusitis prevalence and hence cause a dip in the growth of the sinusitis market.

Report Metrics	Details
Study Period	2019–2032
Coverage	7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year	2019
Key Sinusitis Companies	Optinose US Inc, GeneOne Life Science, Lyra Therapeutics, Sanofi, Regeneron Pharmaceuticals, Genentech, AstraZeneca, Sanofi, Bayer, Pfizer, TRELLIS BIOSCIENCE, Sanotize Research and Development, OptiNose, Biohaven Pharmaceuticals, Keymed Biosciences Co.Ltd, Suzhou Connect Biopharmaceuticals, Ltd., BEAM Alliance, Insmed Incorporated, Lanier Biotherapeutics, GlycoMira, IVIEW Therapeutics Inc., Nota Laboratories LLC, Quorum Innovations, and others
Key Sinusitis Therapies	OPN-375, Quinine topical nasal spray, Mometasone eluting resorbable scaffold, Dupilumab, Omalizumab, Benralizumab, Telithromycin, Moxifloxacin, PF-06817024, and others

Scope of the Sinusitis Market Report

Therapeutic Assessment: Sinusitis current marketed and emerging therapies
Sinusitis Market Dynamics: Attribute Analysis of Emerging Sinusitis Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Sinusitis Market Access and Reimbursement

Discover more about sinusitis drugs in development @ Sinusitis Clinical Trials

Table of Contents

1.	Sinusitis Market Key Insights
2.	Sinusitis Market Report Introduction
3.	Sinusitis Market Overview at a Glance
4.	Sinusitis Market Executive Summary
5.	Disease Background and Overview
6.	Sinusitis Treatment and Management
7.	Sinusitis Epidemiology and Patient Population
8.	Patient Journey
9.	Sinusitis Marketed Drugs
10.	Sinusitis Emerging Drugs
11.	Seven Major Sinusitis Market Analysis
12.	Sinusitis Market Outlook
13.	Potential of Current and Emerging Therapies
14.	KOL Views
15.	Unmet Needs
16.	SWOT Analysis
17.	Appendix
18.	DelveInsight Capabilities
19.	Disclaimer
20.	About DelveInsight

Related Reports

Sinusitis Pipeline

Sinusitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sinusitis companies, including GeneOne Life Science, Lyra Therapeutics, TRELLIS BIOSCIENCE, Sanotize Research and Development, Sanofi, OptiNose, Biohaven Pharmaceuticals, Keymed Biosciences Co.Ltd, Suzhou Connect Biopharmaceuticals, Ltd., Genentech, Inc., Pfizer, among others.

Sinusitis Epidemiology Forecast

Sinusitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted sinusitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Rhinosinusitis Market

Rhinosinusitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key rhinosinusitis companies, including Kyowa Kirin Co., Ltd., Keymed Biosciences Co.Ltd, Pfizer, GlycoMira Therapeutics, among others.

Rhinosinusitis Pipeline

Rhinosinusitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key rhinosinusitis companies, including Kyowa Kirin Co., Ltd., Keymed Biosciences Co.Ltd, Pfizer, GlycoMira Therapeutics, among others.

Chronic Rhinosinusitis Market

Chronic Rhinosinusitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key chronic rhinosinusitis companies, including Connect Biopharma, Lyra Therapeutics, Sanotize Research and Development corp., Regeneron Pharmaceuticals, AstraZeneca, among others.

Chronic Rhinosinusitis Pipeline

Chronic Rhinosinusitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic rhinosinusitis companies, including Connect Biopharma, Lyra Therapeutics, Sanotize Research and Development corp., Regeneron Pharmaceuticals, AstraZeneca, among others.

Other Trending Reports

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Related Topics:AI Artificial Intelligence Machine learning

Up Next

Logiq Appoints Technology Visionary and Investor, Peter Bordes, to Board of Directors

Don't Miss

Global Plant Biostimulants Strategic Business Report 2023: Shrinking Arable Land Drives Demand for Biostimulants

GlobeNewswire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Dongfa Group’s Gas Scenario + Digital Twin Technology, Leads the Industry with New AI Trend

Published

1 hour ago

May 23, 2024

CISION (PR Newswire)

dongfa-group’s-gas-scenario-+-digital-twin-technology,-leads-the-industry-with-new-ai-trend

–Highlights of the 2024 Exhibition
SHANGHAI, May 23, 2024 /PRNewswire/ — From May 17 to 19, 2024, China(Shanghai) International Metrology Measurement Technology and Equipment Exhibition was held at the Shanghai World Expo Exhibition and Convention Center. Dongfa Group participated in the exhibition, showcasing its latest research achievements. At the expo, Chairman Liu Ming of Dongfa Group conducted the lighting ceremony and announced the official launch of the “Smart Gas Comprehensive Supervision Platform,” demonstrating the convenience and efficiency achieved through the smart management of municipal gas meters.

Dandong Dongfa (Group) Co., Ltd., established in 1962 and headquartered in Singapore, was formerly known as Dandong Thermal Instrument Co., Ltd. As an integrated group company engaged in research, production, and operations, Dongfa Group is dedicated to the development and application of instruments and meters. Its product range includes IC card gas meters, wired direct-reading remote diaphragm gas meters, wireless direct-reading remote diaphragm gas meters, NB-IoT IoT meters, and ultrasonic gas meters. These products incorporate the technical features of similar domestic and international products, offering high accuracy, reliability, and stability, making the company a leading smart gas meter manufacturer in China.
At the expo, Dongfa Group showcased its Smart Gas Comprehensive Supervision Platform, which integrates AI, IoT, cloud computing, and big data. This platform connects the topological structure of all aspects of gas operations and consolidates all relevant data involved in production management and operation maintenance. This integration enhances the comprehensive research and development and operational maintenance capabilities of the big data governance system.
At the same time, Dongfa Group is empowering comprehensive management and control with digital twins, AI, and big data. By leveraging digital twins, AI models, and 5G technology as data elements, the company is constructing a unified citywide network and a digital twin map of the gas pipeline network. This enables deep integration of AI monitoring, pressure and leakage detection, smart terminals, and other sensing devices with gas operations, ensuring the comprehensive safety and supply of urban gas.
Digital twin gas technology not only provides auxiliary support for pipeline design, but also plays a crucial role in intelligent emergency response and precise distribution. Especially in the operation of gas stations, it enables comprehensive real-time monitoring, intelligent integrated operation scheduling, proactive warning, emergency event command plans, and other effects, thereby improving the efficiency and safety of gas management.
However, there have been numerous incidents of data leakage involving smart AI devices in recent years. Sensitive data is being collected or even sold by malicious actors, leading to the disclosure of confidential information, resulting in significant economic losses and even legal risks.
To ensure the security of both enterprise and user data, Dongfa Group utilizes Digital Envelope technology to encrypt and decrypt data packets during data collection and distribution. This approach combines the advantages of both symmetric and asymmetric encryption technologies for secure information transmission, enabling fast, efficient, and secure encryption and decryption processing for the smart gas digital business sector. This ensures the security and integrity of data during transmission.
Visitors at the expo showed strong interest in the new products and technologies exhibited by Dongfa Group. Dongfa Group has always been committed to driving the development of the smart instrumentation industry through technological innovation. Through this exhibition, the company not only showcased its technical prowess but also strengthened communication and collaboration with industry peers. Looking ahead, they aim to join hands in opening a new chapter in the smart instrumentation industry.
Photo – https://mma.prnewswire.com/media/2420352/Dongfa_Group_s_Gas_Scenario___Digital_Twin_Technology__Leads_the_Industry_with_New_AI_Trend.jpg

View original content:https://www.prnewswire.co.uk/news-releases/dongfa-groups-gas-scenario–digital-twin-technology-leads-the-industry-with-new-ai-trend-302153974.html

Artificial Intelligence

QNAP S3-compatible Storage Solution “QuObjects” Certified as Veeam® Ready – Object with Immutability

Published

1 hour ago

May 23, 2024

CISION (PR Newswire)

qnap-s3-compatible-storage-solution-“quobjects”-certified-as-veeam-ready-–-object-with-immutability

TAIPEI, May 23, 2024 /PRNewswire/ — QNAP® Systems, Inc., a leading computing, networking, and storage solution innovator, today announced that its S3-compatible object storage solution “QuObjects” has qualified as Veeam® Ready – Object with Immutability, applicable for QNAP NAS with QTS and QuTS hero operating systems. This certification underscores the reliability of QuObjects as a secure object backup solution for enterprises, enhancing data management efficiency and upmost security.

QuObjects is the S3 object storage solution for QNAP NAS, boasting read/write speeds 20 times faster than conventional cloud services, along with a highly flexible and scalable architecture to ensure efficient transmission and flexibility in object storage. From object service development to demanding workloads like machine learning and data lakes, QuObjects assists enterprises in achieving diverse application needs with higher cost effectiveness.
QuObjects supports Object Lock to ensure data immutability, further safeguarding against ransomware threats, cyberattacks, or human error. Coupled with access controls and authentication features, it provides comprehensive protection for object data security.
Jimmy Tam, Product Manager of QNAP, stated “Data security is critical for enterprises. With QuObjects certified by Veeam Ready – Object with Immutability, we empower organizations leveraging Veeam solutions to confidently opt for QNAP NAS for on-prem S3 object storage and backup, enjoying rapid transmission, extensive scalability, and steadfast security.”
QNAP is the preferred partner for Veeam object backup solutions. Learn more at Veeam Ready Object Partner and QNAP QuObjects- S3 Object Storage.
For more information and to view the full QNAP NAS lineup, please visit www.qnap.com.
Photo – https://mma.prnewswire.com/media/2413244/PR_image_QNAP_x_Veeam_Ready_en.jpg

View original content:https://www.prnewswire.co.uk/news-releases/qnap-s3-compatible-storage-solution-quobjects-certified-as-veeam-ready–object-with-immutability-302148872.html

Artificial Intelligence

Tencent Announces Winners of Flagship CarbonX Program to Combat Climate Change

Published

5 hours ago

May 23, 2024

CISION (PR Newswire)

SHENZHEN, China, May 23, 2024 /PRNewswire/ — Tencent (00700.HK) is awarding 13 exceptional teams that won the first phase of its groundbreaking CarbonX Program, which is aimed at boosting promising new climate technologies. The winners, which emerged from a pool of 30 finalists and more than 300 initial applications, will receive a total of around RMB 100 million (US$14 million) in financial support from Tencent. It showcases the company’s commitment to driving sustainable social innovations in the fight against climate change.

CarbonX was launched in March 2023 to advance the next generation of low-carbon technologies. Tencent has committed RMB 200 million (US$28 million) in catalytic funding over the next three years to innovative ideas that might otherwise languish or fail to gain traction.
CarbonX’s first phase focused on carbon capture, utilization, and storage (CCUS), as well as technology-based carbon removal. These solutions were chosen for their unique ability to curb emissions from hard-to-abate industries such as steel and cement, mitigate the continued reliance on fossil fuels, and reduce legacy emissions created from decades of industrialization.
Backed by Tencent’s mission of Tech for Good and an alliance of like-minded industry partners, CarbonX aims to help these cutting-edge technologies make the leap from the research or early startup stage to commercial scale. The ultimate goal is supporting them in making a significant impact toward the targets outlined in the Paris Agreement, which includes a 45 percent reduction in emissions by 2030 and achieving net-zero emissions by 2050.
Dr. Hao Xu, Tencent’s Vice President of Sustainable Social Value and Head of Tencent’s Carbon Neutrality Lab, said: “Technology innovation serves as the driving force to accelerate our progress toward achieving carbon neutrality. CarbonX program is aimed at fostering the growth of these technologies, driving positive impact across society, and laying the groundwork for a more sustainable future.”
Professor Jerry Yan, Chair Professor of the Hong Kong Polytechnic University and Co-chairman of the CarbonX expert committee, said: “To pave the path for a greener economy, we must champion the development of cutting-edge low-carbon technologies. Just as solar and wind power were nurtured in their infancy, emerging solutions like CCUS and tech-based carbon removal demand our early support.”
The program assembled a panel of experts from academia, industries, and the investor community as the jury, and welcomed submissions from diverse participants across three distinct tracks:
CarbonX Lab: Designed to incubate research institutions, universities, or labs that bring in game-changing climate solutionsCarbonX Accelerator: Designed to accelerate the growth of climate-tech startups that exhibit commercialization potentialCarbonX Infrastructure: Designed to support capacity building to facilitate industry developmentThe finalists comprise four projects from the Lab track, six from the Accelerator track, and three from the Infrastructure track. These projects explore innovative solutions, such as using steel slag to capture and store carbon directly from furnace exhaust, converting CO2 into sustainable aviation fuel and valuable chemicals through electrochemical reactions or microorganisms, and employing new approaches to directly capture CO2 from the atmosphere with the hope of slashing the cost to less than US$150 per ton.
Meanwhile, Tencent is also collaborating with Tsinghua University to develop a comprehensive system of Measure, Reporting and Verification (MRV) tools to accurately gauge progress toward decarbonization.
Aside from receiving financial and advisory support, several projects will also have the opportunity to collaborate with industry partners and test their research beyond the laboratory setting.
Building upon the success of the first phase, Tencent is poised to launch the second iteration of CarbonX globally as early as later this year in pursuit of early-stage climate tech innovation.

View original content:https://www.prnewswire.co.uk/news-releases/tencent-announces-winners-of-flagship-carbonx-program-to-combat-climate-change-302153596.html